DNA �-Amyloid1-42 Trimer Immunization for Alzheimer Disease in a Wild-Type Mouse Model
JAMA 302:1796-1802, Lambracht-Washington,D.,et al, 2009
Long-Term Effects of A�42 Immunisation in Alzheimers Disease: Follow-Up of a Randomised, Placebo-Controlled Phase I Trial
Lancet 372:216-223,180, Holmes,C.,et al., 2008
A-beta Vaccination Effects on Plaque Pathology in the Absence of Encephalitis in Alzheimer Disease
Neurol 64:129-131,10, Masliah,E.,et al, 2005
Subacute Meningoencephalitis in a Subset of Patients with AD After AB42 Immunization
Neurol 61:46-54,7, Orgogozo,J.M.,et al, 2003
Immunization for Alzheimer's Disease: A Shot in the Arm or a Whiff?
Ann Neurol 48:553-555, Levey,A.I., 2000
Immunologic Treatment of Alzheimer's Disease
NEJM 341:1694-1695, Blass,J.P., 1999
Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Cognitive and Clinical Characteristics of Patients with Limbic-Predominant Age-Related TDP-43 Encephalopathy
Neurol 100:e2027-e2035, Pagnotti,R.M.B.,et al, 2023
Monkeypox-Associated Central Nervous System Disease:A Case Series and Review
Ann Neurol 93:893-905, Money,K.M.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Toward Gerineuropalliative Care for Patients with Dementia
NEJM 389:775-778, Harrison,K.L.,et al, 2023
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients with Early Alzheimer Disease
Neurol 98:e968-e977, Whittington, M.D.,et al, 2022
Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System
Ann Neurol 91:756-771, Frontera, J.A.,et al, 2022
What All Physicians Need to Know About the Polio Resurgence in New York State
JAMA online e1-e3, Larkin, H., 2022
An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022
Re-Emergency of Poliovirus in the United States:Considerations and Implications
Ann Neurol 92:725-728, Russo,G.B.,et al, 2022
Clinical Manifestation,Management,and Outcomes in Patients with COVID-19 Vaccine-Induced Acute Encephalitis:Two Case Reports and a Literature Review
Vaccines 10:1230, Shyu,S.,et al, 2022
COVID-19-Booster Vaccine-Induced Encephalitis
Acta Neurol Belg 122:579-581, Sluyts,Y.,et al, 2022
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
The Effects of Long-Term Medication Use in Alzheimer Disease
Neurol 96:e2247-e2250, Karceski, S., 2021
Bilateral Superior Ophthalmic Vein Thrombosis, Ischaemic Stroke, and Immune Thrombocytopenia After ChAdOx1 nCoV-19 Vaccination
Lancet 397:e11, Bayas, A.,et al, 2021
ANA Investigates: Neurological Complications of Covid-19 Vaccines
Ann Neurol 89:856-857, Goss, A.L.,et al, 2021
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Ad26.COV2.S Vaccination, March 2 to April 21, 2021
JAMA 325:2448-2456,2445, See, I.,et al, 2021
Cerebral Venous Thrombosis
NEJM 385:59-64, Ropper, A.H. & Kline, J.P., 2021
Helping with Public Understand Adverse Events Associated with Covid-19 Vaccinations
JAMA Neurol 78:789-790, Kim, D.D.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Vaccine-Induced Thrombocytopenia with Severe Headache
NEJM 385:doi:101056/NE0a2114255, Schonborn, L., et al, 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Vaccine-Induced Thrombocytopenia with Severe Headache
NEJM 385:doi:10.1056/NEJMc2112974, Salih, F.,et al, 2021
Application of Deep Learning to Predict Standardized Uptake Value Ratio and Amyloid Status on 18F-Florbetapir PET Using ADNI Data
AJNR 41:980-986, Reith, F.,et al, 2020
A Teenager with Persistent Headache
Neurol 92:e1526-e1531, Hu, Y.,et al, 2019
Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE): Consensus Working Group Report
Brain DOI: 10.1093/brain/awz099, Nelson, P.T.,et al, 2019
Debate Sparks Over LATE, a Recently Recognized Dementia
JAMA 322:914-916, Abbasi, J., 2019
Vaccine-Preventable Infections and Immunization in Multiple Sclerosis
Neurol 93:584-594, Farez, M.F.,et al, 2019
Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
Paraoxysmal Tonic Upgaze in Children, Three Case Reports and a Review of the Literature
Pediatr Emer Care 35:e67-e69, Kartal,A., 2019
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018
Clinicopathologic Conference, Primary Progressive Aphasia, Semantic Variant, due to TAR DNA Binding Protein 43 associated Frontotemporal Lobar Degen
NEJM 376:158-167, Case 1-2017, 2017
Clinicopathologic Conference, Posterior Cortical Atrophy with Frontotemporal Lobe Dementia with Gene Mutation
JAMA Neurol 74:114-118, , 2017
Neurofilament as a Blood Marker for Diagnosis and Monitoring of Primary Progressive Aphasias
Neurol 88:961-969, Steinacker, P.,et al, 2017
Outcomes after Diagnosis of Mild Cognitive Impairment in a Large Autopsy Series
Ann Neurol 81:549-559, Abner, E.L.,et al, 2017
Diagnosis and Management of Dementia with Lewy Bodies
Neurol 89:88-100, McKeith, I.G.,et al, 2017
Odor Identification as a Biomarker of Preclinical AD in Older Adults at Risk
Neurol 89:327-335, Lafaille-Magnanm, M.E.,et al, 2017